Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2026 · 10-Q
Revenue$9.03M$9.03M−21.6% vs Q1 2025 Net Income$721.00K$721.00K−56.2% vs Q1 2025 EPS Diluted$0.03$0.03−50.0% vs Q1 2025 Gross Profit$5,904,000−19.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow$283,000−77.1% Free Cash Flowderived$142,000— Margins · derivedGross margin65.4%+1.4 pt vs Q1 2025
Operating margin12.4%−3.5 pt vs Q1 2025
Net margin8.0%−6.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 12, 2026 · 42 d after period end